Ipratropium Bromide

Hyperkalemia, Acute Bronchitis, Pneumonia + 18 more
Treatment
9 FDA approvals
20 Active Studies for Ipratropium Bromide

What is Ipratropium Bromide

SalbutamolThe Generic name of this drug
Treatment SummaryIpratropium is an anticholinergic medication that is taken through inhalation. It was developed by Boehringer Ingelheim and was approved by the FDA in 1986 for individual use and 1996 for use in combination with albuterol. It works by producing a local effect but does not cause significant absorption into the body.
Proair HFAis the brand name
image of different drug pills on a surface
Ipratropium Bromide Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Proair HFA
Salbutamol
1981
314

Approved as Treatment by the FDA

Salbutamol, also known as Proair HFA, is approved by the FDA for 9 uses like prophylaxis of Bronchospasm and prophylaxis of Exercise-induced bronchospasm .
prophylaxis of Bronchospasm
prophylaxis of Exercise-induced bronchospasm
Bronchospasm, Exercise-Induced
Bronchial Spasm
Asthma, Exercise-Induced
Chronic Obstructive Pulmonary Disease
Used to treat Chronic Obstructive Pulmonary Disease (COPD) in combination with Ipratropium
Bronchodilator Agents
Used to treat need of more than one bronchodilator in combination with Ipratropium
Exercise-Induced Bronchospasm
Bronchospasm

Effectiveness

How Ipratropium Bromide Affects PatientsIpratropium is a medication that helps to relax the muscles in your airways and makes it easier to breathe. It usually takes 1-2 hours for this medication to start working and its effects typically last between 4-6 hours. In clinical trials, ipratropium was found to help improve breathing and lung function in people with asthma. However, it is not known if taking ipratropium regularly or as a preventative measure is beneficial.
How Ipratropium Bromide works in the bodyIpratropium works by blocking the activity of acetylcholine in the airways, which prevents them from constricting. This effect allows the airways to stay relaxed and open, leading to bronchodilation and fewer secretions. At the cellular level, ipratroium stops the acetylcholine from contracting the muscle cells and narrowing the airways.

When to interrupt dosage

The prescribed dosage of Ipratropium Bromide is contingent upon the indicated condition, including Chronic Obstructive Pulmonary Disease (COPD), Asthma and Non-Allergic Rhinitis. The measure of dosage fluctuates, as per the administration approach noted in the table below.
Condition
Dosage
Administration
excess mucus or phlegm
2.0 mg/mL, , 2.5 mg/mL, 0.09 mg, 3.0 mg/mL, 2.0 mg, 4.0 mg, 8.0 mg, 0.75 mg/mL, 1.5 mg/mL, 25.0 mg/mL, 0.63 mg/mL, 1.25 mg/mL, 0.108 mg, 5.0 mg/mL, 2.4 mg, 0.045 mg, 3.0 mg, 0.4 mg, 0.2 mg, 0.1 mg, 0.05 %, 0.1 %, 0.2 %, 0.83 mg/mL, 0.12 mg, 4.8 mg, 0.00009 mg/mg, 1.0 mg/mL, 0.1 mg/dose, 0.5 mg/mL, 0.2 mg/pump actuation, 0.097 mg/pump actuation, 0.1 mg/pump actuation, 0.4 mg/mL, 0.25 mg/mL, 0.12 mg/pump actuation
, Oral, Syrup, Syrup - Oral, Respiratory (inhalation), Solution, Aerosol, metered, Aerosol, metered - Respiratory (inhalation), Tablet, Tablet - Oral, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Solution - Respiratory (inhalation), Intrabronchial, Solution - Intrabronchial, Aerosol, metered - Oral, Occlusive dressing technique, Syrup - Occlusive dressing technique, Tablet, extended release, Tablet, extended release - Oral, Powder, Powder - Respiratory (inhalation), Liquid, Intramuscular, Liquid - Intramuscular, Capsule - Respiratory (inhalation), Capsule, Solution - Intramuscular, Liquid - Respiratory (inhalation), Spray, metered, Powder, metered, Powder, metered - Respiratory (inhalation), Intravenous, Spray, metered - Respiratory (inhalation), Aerosol, spray - Oral, Aerosol, spray, Spray, Spray - Oral, Aerosol, metered - Intrabronchial, Nasal, Inhalant - Oral, Inhalant, Solution - Nasal, Inhalant - Respiratory (inhalation), Solution - Oral, Solution - Intravenous, Liquid - Intravenous, Liquid - Oral, Inhalant - Nasal
Hyperkalemia
2.0 mg/mL, , 2.5 mg/mL, 0.09 mg, 3.0 mg/mL, 2.0 mg, 4.0 mg, 8.0 mg, 0.75 mg/mL, 1.5 mg/mL, 25.0 mg/mL, 0.63 mg/mL, 1.25 mg/mL, 0.108 mg, 5.0 mg/mL, 2.4 mg, 0.045 mg, 3.0 mg, 0.4 mg, 0.2 mg, 0.1 mg, 0.05 %, 0.1 %, 0.2 %, 0.83 mg/mL, 0.12 mg, 4.8 mg, 0.00009 mg/mg, 1.0 mg/mL, 0.1 mg/dose, 0.5 mg/mL, 0.2 mg/pump actuation, 0.097 mg/pump actuation, 0.1 mg/pump actuation, 0.4 mg/mL, 0.25 mg/mL, 0.12 mg/pump actuation
, Oral, Syrup, Syrup - Oral, Respiratory (inhalation), Solution, Aerosol, metered, Aerosol, metered - Respiratory (inhalation), Tablet, Tablet - Oral, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Solution - Respiratory (inhalation), Intrabronchial, Solution - Intrabronchial, Aerosol, metered - Oral, Occlusive dressing technique, Syrup - Occlusive dressing technique, Tablet, extended release, Tablet, extended release - Oral, Powder, Powder - Respiratory (inhalation), Liquid, Intramuscular, Liquid - Intramuscular, Capsule - Respiratory (inhalation), Capsule, Solution - Intramuscular, Liquid - Respiratory (inhalation), Spray, metered, Powder, metered, Powder, metered - Respiratory (inhalation), Intravenous, Spray, metered - Respiratory (inhalation), Aerosol, spray - Oral, Aerosol, spray, Spray, Spray - Oral, Aerosol, metered - Intrabronchial, Nasal, Inhalant - Oral, Inhalant, Solution - Nasal, Inhalant - Respiratory (inhalation), Solution - Oral, Solution - Intravenous, Liquid - Intravenous, Liquid - Oral, Inhalant - Nasal
Acute Bronchitis
2.0 mg/mL, , 2.5 mg/mL, 0.09 mg, 3.0 mg/mL, 2.0 mg, 4.0 mg, 8.0 mg, 0.75 mg/mL, 1.5 mg/mL, 25.0 mg/mL, 0.63 mg/mL, 1.25 mg/mL, 0.108 mg, 5.0 mg/mL, 2.4 mg, 0.045 mg, 3.0 mg, 0.4 mg, 0.2 mg, 0.1 mg, 0.05 %, 0.1 %, 0.2 %, 0.83 mg/mL, 0.12 mg, 4.8 mg, 0.00009 mg/mg, 1.0 mg/mL, 0.1 mg/dose, 0.5 mg/mL, 0.2 mg/pump actuation, 0.097 mg/pump actuation, 0.1 mg/pump actuation, 0.4 mg/mL, 0.25 mg/mL, 0.12 mg/pump actuation
, Oral, Syrup, Syrup - Oral, Respiratory (inhalation), Solution, Aerosol, metered, Aerosol, metered - Respiratory (inhalation), Tablet, Tablet - Oral, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Solution - Respiratory (inhalation), Intrabronchial, Solution - Intrabronchial, Aerosol, metered - Oral, Occlusive dressing technique, Syrup - Occlusive dressing technique, Tablet, extended release, Tablet, extended release - Oral, Powder, Powder - Respiratory (inhalation), Liquid, Intramuscular, Liquid - Intramuscular, Capsule - Respiratory (inhalation), Capsule, Solution - Intramuscular, Liquid - Respiratory (inhalation), Spray, metered, Powder, metered, Powder, metered - Respiratory (inhalation), Intravenous, Spray, metered - Respiratory (inhalation), Aerosol, spray - Oral, Aerosol, spray, Spray, Spray - Oral, Aerosol, metered - Intrabronchial, Nasal, Inhalant - Oral, Inhalant, Solution - Nasal, Inhalant - Respiratory (inhalation), Solution - Oral, Solution - Intravenous, Liquid - Intravenous, Liquid - Oral, Inhalant - Nasal
Bronchial Spasm
2.0 mg/mL, , 2.5 mg/mL, 0.09 mg, 3.0 mg/mL, 2.0 mg, 4.0 mg, 8.0 mg, 0.75 mg/mL, 1.5 mg/mL, 25.0 mg/mL, 0.63 mg/mL, 1.25 mg/mL, 0.108 mg, 5.0 mg/mL, 2.4 mg, 0.045 mg, 3.0 mg, 0.4 mg, 0.2 mg, 0.1 mg, 0.05 %, 0.1 %, 0.2 %, 0.83 mg/mL, 0.12 mg, 4.8 mg, 0.00009 mg/mg, 1.0 mg/mL, 0.1 mg/dose, 0.5 mg/mL, 0.2 mg/pump actuation, 0.097 mg/pump actuation, 0.1 mg/pump actuation, 0.4 mg/mL, 0.25 mg/mL, 0.12 mg/pump actuation
, Oral, Syrup, Syrup - Oral, Respiratory (inhalation), Solution, Aerosol, metered, Aerosol, metered - Respiratory (inhalation), Tablet, Tablet - Oral, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Solution - Respiratory (inhalation), Intrabronchial, Solution - Intrabronchial, Aerosol, metered - Oral, Occlusive dressing technique, Syrup - Occlusive dressing technique, Tablet, extended release, Tablet, extended release - Oral, Powder, Powder - Respiratory (inhalation), Liquid, Intramuscular, Liquid - Intramuscular, Capsule - Respiratory (inhalation), Capsule, Solution - Intramuscular, Liquid - Respiratory (inhalation), Spray, metered, Powder, metered, Powder, metered - Respiratory (inhalation), Intravenous, Spray, metered - Respiratory (inhalation), Aerosol, spray - Oral, Aerosol, spray, Spray, Spray - Oral, Aerosol, metered - Intrabronchial, Nasal, Inhalant - Oral, Inhalant, Solution - Nasal, Inhalant - Respiratory (inhalation), Solution - Oral, Solution - Intravenous, Liquid - Intravenous, Liquid - Oral, Inhalant - Nasal
Asthma
2.0 mg/mL, , 2.5 mg/mL, 0.09 mg, 3.0 mg/mL, 2.0 mg, 4.0 mg, 8.0 mg, 0.75 mg/mL, 1.5 mg/mL, 25.0 mg/mL, 0.63 mg/mL, 1.25 mg/mL, 0.108 mg, 5.0 mg/mL, 2.4 mg, 0.045 mg, 3.0 mg, 0.4 mg, 0.2 mg, 0.1 mg, 0.05 %, 0.1 %, 0.2 %, 0.83 mg/mL, 0.12 mg, 4.8 mg, 0.00009 mg/mg, 1.0 mg/mL, 0.1 mg/dose, 0.5 mg/mL, 0.2 mg/pump actuation, 0.097 mg/pump actuation, 0.1 mg/pump actuation, 0.4 mg/mL, 0.25 mg/mL, 0.12 mg/pump actuation
, Oral, Syrup, Syrup - Oral, Respiratory (inhalation), Solution, Aerosol, metered, Aerosol, metered - Respiratory (inhalation), Tablet, Tablet - Oral, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Solution - Respiratory (inhalation), Intrabronchial, Solution - Intrabronchial, Aerosol, metered - Oral, Occlusive dressing technique, Syrup - Occlusive dressing technique, Tablet, extended release, Tablet, extended release - Oral, Powder, Powder - Respiratory (inhalation), Liquid, Intramuscular, Liquid - Intramuscular, Capsule - Respiratory (inhalation), Capsule, Solution - Intramuscular, Liquid - Respiratory (inhalation), Spray, metered, Powder, metered, Powder, metered - Respiratory (inhalation), Intravenous, Spray, metered - Respiratory (inhalation), Aerosol, spray - Oral, Aerosol, spray, Spray, Spray - Oral, Aerosol, metered - Intrabronchial, Nasal, Inhalant - Oral, Inhalant, Solution - Nasal, Inhalant - Respiratory (inhalation), Solution - Oral, Solution - Intravenous, Liquid - Intravenous, Liquid - Oral, Inhalant - Nasal
prophylaxis of Bronchospasm
2.0 mg/mL, , 2.5 mg/mL, 0.09 mg, 3.0 mg/mL, 2.0 mg, 4.0 mg, 8.0 mg, 0.75 mg/mL, 1.5 mg/mL, 25.0 mg/mL, 0.63 mg/mL, 1.25 mg/mL, 0.108 mg, 5.0 mg/mL, 2.4 mg, 0.045 mg, 3.0 mg, 0.4 mg, 0.2 mg, 0.1 mg, 0.05 %, 0.1 %, 0.2 %, 0.83 mg/mL, 0.12 mg, 4.8 mg, 0.00009 mg/mg, 1.0 mg/mL, 0.1 mg/dose, 0.5 mg/mL, 0.2 mg/pump actuation, 0.097 mg/pump actuation, 0.1 mg/pump actuation, 0.4 mg/mL, 0.25 mg/mL, 0.12 mg/pump actuation
, Oral, Syrup, Syrup - Oral, Respiratory (inhalation), Solution, Aerosol, metered, Aerosol, metered - Respiratory (inhalation), Tablet, Tablet - Oral, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Solution - Respiratory (inhalation), Intrabronchial, Solution - Intrabronchial, Aerosol, metered - Oral, Occlusive dressing technique, Syrup - Occlusive dressing technique, Tablet, extended release, Tablet, extended release - Oral, Powder, Powder - Respiratory (inhalation), Liquid, Intramuscular, Liquid - Intramuscular, Capsule - Respiratory (inhalation), Capsule, Solution - Intramuscular, Liquid - Respiratory (inhalation), Spray, metered, Powder, metered, Powder, metered - Respiratory (inhalation), Intravenous, Spray, metered - Respiratory (inhalation), Aerosol, spray - Oral, Aerosol, spray, Spray, Spray - Oral, Aerosol, metered - Intrabronchial, Nasal, Inhalant - Oral, Inhalant, Solution - Nasal, Inhalant - Respiratory (inhalation), Solution - Oral, Solution - Intravenous, Liquid - Intravenous, Liquid - Oral, Inhalant - Nasal
Respiratory Tract Infections
2.0 mg/mL, , 2.5 mg/mL, 0.09 mg, 3.0 mg/mL, 2.0 mg, 4.0 mg, 8.0 mg, 0.75 mg/mL, 1.5 mg/mL, 25.0 mg/mL, 0.63 mg/mL, 1.25 mg/mL, 0.108 mg, 5.0 mg/mL, 2.4 mg, 0.045 mg, 3.0 mg, 0.4 mg, 0.2 mg, 0.1 mg, 0.05 %, 0.1 %, 0.2 %, 0.83 mg/mL, 0.12 mg, 4.8 mg, 0.00009 mg/mg, 1.0 mg/mL, 0.1 mg/dose, 0.5 mg/mL, 0.2 mg/pump actuation, 0.097 mg/pump actuation, 0.1 mg/pump actuation, 0.4 mg/mL, 0.25 mg/mL, 0.12 mg/pump actuation
, Oral, Syrup, Syrup - Oral, Respiratory (inhalation), Solution, Aerosol, metered, Aerosol, metered - Respiratory (inhalation), Tablet, Tablet - Oral, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Solution - Respiratory (inhalation), Intrabronchial, Solution - Intrabronchial, Aerosol, metered - Oral, Occlusive dressing technique, Syrup - Occlusive dressing technique, Tablet, extended release, Tablet, extended release - Oral, Powder, Powder - Respiratory (inhalation), Liquid, Intramuscular, Liquid - Intramuscular, Capsule - Respiratory (inhalation), Capsule, Solution - Intramuscular, Liquid - Respiratory (inhalation), Spray, metered, Powder, metered, Powder, metered - Respiratory (inhalation), Intravenous, Spray, metered - Respiratory (inhalation), Aerosol, spray - Oral, Aerosol, spray, Spray, Spray - Oral, Aerosol, metered - Intrabronchial, Nasal, Inhalant - Oral, Inhalant, Solution - Nasal, Inhalant - Respiratory (inhalation), Solution - Oral, Solution - Intravenous, Liquid - Intravenous, Liquid - Oral, Inhalant - Nasal
Bronchitis
2.0 mg/mL, , 2.5 mg/mL, 0.09 mg, 3.0 mg/mL, 2.0 mg, 4.0 mg, 8.0 mg, 0.75 mg/mL, 1.5 mg/mL, 25.0 mg/mL, 0.63 mg/mL, 1.25 mg/mL, 0.108 mg, 5.0 mg/mL, 2.4 mg, 0.045 mg, 3.0 mg, 0.4 mg, 0.2 mg, 0.1 mg, 0.05 %, 0.1 %, 0.2 %, 0.83 mg/mL, 0.12 mg, 4.8 mg, 0.00009 mg/mg, 1.0 mg/mL, 0.1 mg/dose, 0.5 mg/mL, 0.2 mg/pump actuation, 0.097 mg/pump actuation, 0.1 mg/pump actuation, 0.4 mg/mL, 0.25 mg/mL, 0.12 mg/pump actuation
, Oral, Syrup, Syrup - Oral, Respiratory (inhalation), Solution, Aerosol, metered, Aerosol, metered - Respiratory (inhalation), Tablet, Tablet - Oral, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Solution - Respiratory (inhalation), Intrabronchial, Solution - Intrabronchial, Aerosol, metered - Oral, Occlusive dressing technique, Syrup - Occlusive dressing technique, Tablet, extended release, Tablet, extended release - Oral, Powder, Powder - Respiratory (inhalation), Liquid, Intramuscular, Liquid - Intramuscular, Capsule - Respiratory (inhalation), Capsule, Solution - Intramuscular, Liquid - Respiratory (inhalation), Spray, metered, Powder, metered, Powder, metered - Respiratory (inhalation), Intravenous, Spray, metered - Respiratory (inhalation), Aerosol, spray - Oral, Aerosol, spray, Spray, Spray - Oral, Aerosol, metered - Intrabronchial, Nasal, Inhalant - Oral, Inhalant, Solution - Nasal, Inhalant - Respiratory (inhalation), Solution - Oral, Solution - Intravenous, Liquid - Intravenous, Liquid - Oral, Inhalant - Nasal
Airway secretion clearance therapy
2.0 mg/mL, , 2.5 mg/mL, 0.09 mg, 3.0 mg/mL, 2.0 mg, 4.0 mg, 8.0 mg, 0.75 mg/mL, 1.5 mg/mL, 25.0 mg/mL, 0.63 mg/mL, 1.25 mg/mL, 0.108 mg, 5.0 mg/mL, 2.4 mg, 0.045 mg, 3.0 mg, 0.4 mg, 0.2 mg, 0.1 mg, 0.05 %, 0.1 %, 0.2 %, 0.83 mg/mL, 0.12 mg, 4.8 mg, 0.00009 mg/mg, 1.0 mg/mL, 0.1 mg/dose, 0.5 mg/mL, 0.2 mg/pump actuation, 0.097 mg/pump actuation, 0.1 mg/pump actuation, 0.4 mg/mL, 0.25 mg/mL, 0.12 mg/pump actuation
, Oral, Syrup, Syrup - Oral, Respiratory (inhalation), Solution, Aerosol, metered, Aerosol, metered - Respiratory (inhalation), Tablet, Tablet - Oral, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Solution - Respiratory (inhalation), Intrabronchial, Solution - Intrabronchial, Aerosol, metered - Oral, Occlusive dressing technique, Syrup - Occlusive dressing technique, Tablet, extended release, Tablet, extended release - Oral, Powder, Powder - Respiratory (inhalation), Liquid, Intramuscular, Liquid - Intramuscular, Capsule - Respiratory (inhalation), Capsule, Solution - Intramuscular, Liquid - Respiratory (inhalation), Spray, metered, Powder, metered, Powder, metered - Respiratory (inhalation), Intravenous, Spray, metered - Respiratory (inhalation), Aerosol, spray - Oral, Aerosol, spray, Spray, Spray - Oral, Aerosol, metered - Intrabronchial, Nasal, Inhalant - Oral, Inhalant, Solution - Nasal, Inhalant - Respiratory (inhalation), Solution - Oral, Solution - Intravenous, Liquid - Intravenous, Liquid - Oral, Inhalant - Nasal
Bronchodilation
2.0 mg/mL, , 2.5 mg/mL, 0.09 mg, 3.0 mg/mL, 2.0 mg, 4.0 mg, 8.0 mg, 0.75 mg/mL, 1.5 mg/mL, 25.0 mg/mL, 0.63 mg/mL, 1.25 mg/mL, 0.108 mg, 5.0 mg/mL, 2.4 mg, 0.045 mg, 3.0 mg, 0.4 mg, 0.2 mg, 0.1 mg, 0.05 %, 0.1 %, 0.2 %, 0.83 mg/mL, 0.12 mg, 4.8 mg, 0.00009 mg/mg, 1.0 mg/mL, 0.1 mg/dose, 0.5 mg/mL, 0.2 mg/pump actuation, 0.097 mg/pump actuation, 0.1 mg/pump actuation, 0.4 mg/mL, 0.25 mg/mL, 0.12 mg/pump actuation
, Oral, Syrup, Syrup - Oral, Respiratory (inhalation), Solution, Aerosol, metered, Aerosol, metered - Respiratory (inhalation), Tablet, Tablet - Oral, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Solution - Respiratory (inhalation), Intrabronchial, Solution - Intrabronchial, Aerosol, metered - Oral, Occlusive dressing technique, Syrup - Occlusive dressing technique, Tablet, extended release, Tablet, extended release - Oral, Powder, Powder - Respiratory (inhalation), Liquid, Intramuscular, Liquid - Intramuscular, Capsule - Respiratory (inhalation), Capsule, Solution - Intramuscular, Liquid - Respiratory (inhalation), Spray, metered, Powder, metered, Powder, metered - Respiratory (inhalation), Intravenous, Spray, metered - Respiratory (inhalation), Aerosol, spray - Oral, Aerosol, spray, Spray, Spray - Oral, Aerosol, metered - Intrabronchial, Nasal, Inhalant - Oral, Inhalant, Solution - Nasal, Inhalant - Respiratory (inhalation), Solution - Oral, Solution - Intravenous, Liquid - Intravenous, Liquid - Oral, Inhalant - Nasal
Bronchodilator Agents
2.0 mg/mL, , 2.5 mg/mL, 0.09 mg, 3.0 mg/mL, 2.0 mg, 4.0 mg, 8.0 mg, 0.75 mg/mL, 1.5 mg/mL, 25.0 mg/mL, 0.63 mg/mL, 1.25 mg/mL, 0.108 mg, 5.0 mg/mL, 2.4 mg, 0.045 mg, 3.0 mg, 0.4 mg, 0.2 mg, 0.1 mg, 0.05 %, 0.1 %, 0.2 %, 0.83 mg/mL, 0.12 mg, 4.8 mg, 0.00009 mg/mg, 1.0 mg/mL, 0.1 mg/dose, 0.5 mg/mL, 0.2 mg/pump actuation, 0.097 mg/pump actuation, 0.1 mg/pump actuation, 0.4 mg/mL, 0.25 mg/mL, 0.12 mg/pump actuation
, Oral, Syrup, Syrup - Oral, Respiratory (inhalation), Solution, Aerosol, metered, Aerosol, metered - Respiratory (inhalation), Tablet, Tablet - Oral, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Solution - Respiratory (inhalation), Intrabronchial, Solution - Intrabronchial, Aerosol, metered - Oral, Occlusive dressing technique, Syrup - Occlusive dressing technique, Tablet, extended release, Tablet, extended release - Oral, Powder, Powder - Respiratory (inhalation), Liquid, Intramuscular, Liquid - Intramuscular, Capsule - Respiratory (inhalation), Capsule, Solution - Intramuscular, Liquid - Respiratory (inhalation), Spray, metered, Powder, metered, Powder, metered - Respiratory (inhalation), Intravenous, Spray, metered - Respiratory (inhalation), Aerosol, spray - Oral, Aerosol, spray, Spray, Spray - Oral, Aerosol, metered - Intrabronchial, Nasal, Inhalant - Oral, Inhalant, Solution - Nasal, Inhalant - Respiratory (inhalation), Solution - Oral, Solution - Intravenous, Liquid - Intravenous, Liquid - Oral, Inhalant - Nasal
Pneumonia
2.0 mg/mL, , 2.5 mg/mL, 0.09 mg, 3.0 mg/mL, 2.0 mg, 4.0 mg, 8.0 mg, 0.75 mg/mL, 1.5 mg/mL, 25.0 mg/mL, 0.63 mg/mL, 1.25 mg/mL, 0.108 mg, 5.0 mg/mL, 2.4 mg, 0.045 mg, 3.0 mg, 0.4 mg, 0.2 mg, 0.1 mg, 0.05 %, 0.1 %, 0.2 %, 0.83 mg/mL, 0.12 mg, 4.8 mg, 0.00009 mg/mg, 1.0 mg/mL, 0.1 mg/dose, 0.5 mg/mL, 0.2 mg/pump actuation, 0.097 mg/pump actuation, 0.1 mg/pump actuation, 0.4 mg/mL, 0.25 mg/mL, 0.12 mg/pump actuation
, Oral, Syrup, Syrup - Oral, Respiratory (inhalation), Solution, Aerosol, metered, Aerosol, metered - Respiratory (inhalation), Tablet, Tablet - Oral, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Solution - Respiratory (inhalation), Intrabronchial, Solution - Intrabronchial, Aerosol, metered - Oral, Occlusive dressing technique, Syrup - Occlusive dressing technique, Tablet, extended release, Tablet, extended release - Oral, Powder, Powder - Respiratory (inhalation), Liquid, Intramuscular, Liquid - Intramuscular, Capsule - Respiratory (inhalation), Capsule, Solution - Intramuscular, Liquid - Respiratory (inhalation), Spray, metered, Powder, metered, Powder, metered - Respiratory (inhalation), Intravenous, Spray, metered - Respiratory (inhalation), Aerosol, spray - Oral, Aerosol, spray, Spray, Spray - Oral, Aerosol, metered - Intrabronchial, Nasal, Inhalant - Oral, Inhalant, Solution - Nasal, Inhalant - Respiratory (inhalation), Solution - Oral, Solution - Intravenous, Liquid - Intravenous, Liquid - Oral, Inhalant - Nasal
Emphysema
2.0 mg/mL, , 2.5 mg/mL, 0.09 mg, 3.0 mg/mL, 2.0 mg, 4.0 mg, 8.0 mg, 0.75 mg/mL, 1.5 mg/mL, 25.0 mg/mL, 0.63 mg/mL, 1.25 mg/mL, 0.108 mg, 5.0 mg/mL, 2.4 mg, 0.045 mg, 3.0 mg, 0.4 mg, 0.2 mg, 0.1 mg, 0.05 %, 0.1 %, 0.2 %, 0.83 mg/mL, 0.12 mg, 4.8 mg, 0.00009 mg/mg, 1.0 mg/mL, 0.1 mg/dose, 0.5 mg/mL, 0.2 mg/pump actuation, 0.097 mg/pump actuation, 0.1 mg/pump actuation, 0.4 mg/mL, 0.25 mg/mL, 0.12 mg/pump actuation
, Oral, Syrup, Syrup - Oral, Respiratory (inhalation), Solution, Aerosol, metered, Aerosol, metered - Respiratory (inhalation), Tablet, Tablet - Oral, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Solution - Respiratory (inhalation), Intrabronchial, Solution - Intrabronchial, Aerosol, metered - Oral, Occlusive dressing technique, Syrup - Occlusive dressing technique, Tablet, extended release, Tablet, extended release - Oral, Powder, Powder - Respiratory (inhalation), Liquid, Intramuscular, Liquid - Intramuscular, Capsule - Respiratory (inhalation), Capsule, Solution - Intramuscular, Liquid - Respiratory (inhalation), Spray, metered, Powder, metered, Powder, metered - Respiratory (inhalation), Intravenous, Spray, metered - Respiratory (inhalation), Aerosol, spray - Oral, Aerosol, spray, Spray, Spray - Oral, Aerosol, metered - Intrabronchial, Nasal, Inhalant - Oral, Inhalant, Solution - Nasal, Inhalant - Respiratory (inhalation), Solution - Oral, Solution - Intravenous, Liquid - Intravenous, Liquid - Oral, Inhalant - Nasal
Asthma
2.0 mg/mL, , 2.5 mg/mL, 0.09 mg, 3.0 mg/mL, 2.0 mg, 4.0 mg, 8.0 mg, 0.75 mg/mL, 1.5 mg/mL, 25.0 mg/mL, 0.63 mg/mL, 1.25 mg/mL, 0.108 mg, 5.0 mg/mL, 2.4 mg, 0.045 mg, 3.0 mg, 0.4 mg, 0.2 mg, 0.1 mg, 0.05 %, 0.1 %, 0.2 %, 0.83 mg/mL, 0.12 mg, 4.8 mg, 0.00009 mg/mg, 1.0 mg/mL, 0.1 mg/dose, 0.5 mg/mL, 0.2 mg/pump actuation, 0.097 mg/pump actuation, 0.1 mg/pump actuation, 0.4 mg/mL, 0.25 mg/mL, 0.12 mg/pump actuation
, Oral, Syrup, Syrup - Oral, Respiratory (inhalation), Solution, Aerosol, metered, Aerosol, metered - Respiratory (inhalation), Tablet, Tablet - Oral, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Solution - Respiratory (inhalation), Intrabronchial, Solution - Intrabronchial, Aerosol, metered - Oral, Occlusive dressing technique, Syrup - Occlusive dressing technique, Tablet, extended release, Tablet, extended release - Oral, Powder, Powder - Respiratory (inhalation), Liquid, Intramuscular, Liquid - Intramuscular, Capsule - Respiratory (inhalation), Capsule, Solution - Intramuscular, Liquid - Respiratory (inhalation), Spray, metered, Powder, metered, Powder, metered - Respiratory (inhalation), Intravenous, Spray, metered - Respiratory (inhalation), Aerosol, spray - Oral, Aerosol, spray, Spray, Spray - Oral, Aerosol, metered - Intrabronchial, Nasal, Inhalant - Oral, Inhalant, Solution - Nasal, Inhalant - Respiratory (inhalation), Solution - Oral, Solution - Intravenous, Liquid - Intravenous, Liquid - Oral, Inhalant - Nasal
Influenza
2.0 mg/mL, , 2.5 mg/mL, 0.09 mg, 3.0 mg/mL, 2.0 mg, 4.0 mg, 8.0 mg, 0.75 mg/mL, 1.5 mg/mL, 25.0 mg/mL, 0.63 mg/mL, 1.25 mg/mL, 0.108 mg, 5.0 mg/mL, 2.4 mg, 0.045 mg, 3.0 mg, 0.4 mg, 0.2 mg, 0.1 mg, 0.05 %, 0.1 %, 0.2 %, 0.83 mg/mL, 0.12 mg, 4.8 mg, 0.00009 mg/mg, 1.0 mg/mL, 0.1 mg/dose, 0.5 mg/mL, 0.2 mg/pump actuation, 0.097 mg/pump actuation, 0.1 mg/pump actuation, 0.4 mg/mL, 0.25 mg/mL, 0.12 mg/pump actuation
, Oral, Syrup, Syrup - Oral, Respiratory (inhalation), Solution, Aerosol, metered, Aerosol, metered - Respiratory (inhalation), Tablet, Tablet - Oral, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Solution - Respiratory (inhalation), Intrabronchial, Solution - Intrabronchial, Aerosol, metered - Oral, Occlusive dressing technique, Syrup - Occlusive dressing technique, Tablet, extended release, Tablet, extended release - Oral, Powder, Powder - Respiratory (inhalation), Liquid, Intramuscular, Liquid - Intramuscular, Capsule - Respiratory (inhalation), Capsule, Solution - Intramuscular, Liquid - Respiratory (inhalation), Spray, metered, Powder, metered, Powder, metered - Respiratory (inhalation), Intravenous, Spray, metered - Respiratory (inhalation), Aerosol, spray - Oral, Aerosol, spray, Spray, Spray - Oral, Aerosol, metered - Intrabronchial, Nasal, Inhalant - Oral, Inhalant, Solution - Nasal, Inhalant - Respiratory (inhalation), Solution - Oral, Solution - Intravenous, Liquid - Intravenous, Liquid - Oral, Inhalant - Nasal
Bronchitis, Chronic
2.0 mg/mL, , 2.5 mg/mL, 0.09 mg, 3.0 mg/mL, 2.0 mg, 4.0 mg, 8.0 mg, 0.75 mg/mL, 1.5 mg/mL, 25.0 mg/mL, 0.63 mg/mL, 1.25 mg/mL, 0.108 mg, 5.0 mg/mL, 2.4 mg, 0.045 mg, 3.0 mg, 0.4 mg, 0.2 mg, 0.1 mg, 0.05 %, 0.1 %, 0.2 %, 0.83 mg/mL, 0.12 mg, 4.8 mg, 0.00009 mg/mg, 1.0 mg/mL, 0.1 mg/dose, 0.5 mg/mL, 0.2 mg/pump actuation, 0.097 mg/pump actuation, 0.1 mg/pump actuation, 0.4 mg/mL, 0.25 mg/mL, 0.12 mg/pump actuation
, Oral, Syrup, Syrup - Oral, Respiratory (inhalation), Solution, Aerosol, metered, Aerosol, metered - Respiratory (inhalation), Tablet, Tablet - Oral, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Solution - Respiratory (inhalation), Intrabronchial, Solution - Intrabronchial, Aerosol, metered - Oral, Occlusive dressing technique, Syrup - Occlusive dressing technique, Tablet, extended release, Tablet, extended release - Oral, Powder, Powder - Respiratory (inhalation), Liquid, Intramuscular, Liquid - Intramuscular, Capsule - Respiratory (inhalation), Capsule, Solution - Intramuscular, Liquid - Respiratory (inhalation), Spray, metered, Powder, metered, Powder, metered - Respiratory (inhalation), Intravenous, Spray, metered - Respiratory (inhalation), Aerosol, spray - Oral, Aerosol, spray, Spray, Spray - Oral, Aerosol, metered - Intrabronchial, Nasal, Inhalant - Oral, Inhalant, Solution - Nasal, Inhalant - Respiratory (inhalation), Solution - Oral, Solution - Intravenous, Liquid - Intravenous, Liquid - Oral, Inhalant - Nasal
Asthma, Exercise-Induced
2.0 mg/mL, , 2.5 mg/mL, 0.09 mg, 3.0 mg/mL, 2.0 mg, 4.0 mg, 8.0 mg, 0.75 mg/mL, 1.5 mg/mL, 25.0 mg/mL, 0.63 mg/mL, 1.25 mg/mL, 0.108 mg, 5.0 mg/mL, 2.4 mg, 0.045 mg, 3.0 mg, 0.4 mg, 0.2 mg, 0.1 mg, 0.05 %, 0.1 %, 0.2 %, 0.83 mg/mL, 0.12 mg, 4.8 mg, 0.00009 mg/mg, 1.0 mg/mL, 0.1 mg/dose, 0.5 mg/mL, 0.2 mg/pump actuation, 0.097 mg/pump actuation, 0.1 mg/pump actuation, 0.4 mg/mL, 0.25 mg/mL, 0.12 mg/pump actuation
, Oral, Syrup, Syrup - Oral, Respiratory (inhalation), Solution, Aerosol, metered, Aerosol, metered - Respiratory (inhalation), Tablet, Tablet - Oral, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Solution - Respiratory (inhalation), Intrabronchial, Solution - Intrabronchial, Aerosol, metered - Oral, Occlusive dressing technique, Syrup - Occlusive dressing technique, Tablet, extended release, Tablet, extended release - Oral, Powder, Powder - Respiratory (inhalation), Liquid, Intramuscular, Liquid - Intramuscular, Capsule - Respiratory (inhalation), Capsule, Solution - Intramuscular, Liquid - Respiratory (inhalation), Spray, metered, Powder, metered, Powder, metered - Respiratory (inhalation), Intravenous, Spray, metered - Respiratory (inhalation), Aerosol, spray - Oral, Aerosol, spray, Spray, Spray - Oral, Aerosol, metered - Intrabronchial, Nasal, Inhalant - Oral, Inhalant, Solution - Nasal, Inhalant - Respiratory (inhalation), Solution - Oral, Solution - Intravenous, Liquid - Intravenous, Liquid - Oral, Inhalant - Nasal
Asthma
2.0 mg/mL, , 2.5 mg/mL, 0.09 mg, 3.0 mg/mL, 2.0 mg, 4.0 mg, 8.0 mg, 0.75 mg/mL, 1.5 mg/mL, 25.0 mg/mL, 0.63 mg/mL, 1.25 mg/mL, 0.108 mg, 5.0 mg/mL, 2.4 mg, 0.045 mg, 3.0 mg, 0.4 mg, 0.2 mg, 0.1 mg, 0.05 %, 0.1 %, 0.2 %, 0.83 mg/mL, 0.12 mg, 4.8 mg, 0.00009 mg/mg, 1.0 mg/mL, 0.1 mg/dose, 0.5 mg/mL, 0.2 mg/pump actuation, 0.097 mg/pump actuation, 0.1 mg/pump actuation, 0.4 mg/mL, 0.25 mg/mL, 0.12 mg/pump actuation
, Oral, Syrup, Syrup - Oral, Respiratory (inhalation), Solution, Aerosol, metered, Aerosol, metered - Respiratory (inhalation), Tablet, Tablet - Oral, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Solution - Respiratory (inhalation), Intrabronchial, Solution - Intrabronchial, Aerosol, metered - Oral, Occlusive dressing technique, Syrup - Occlusive dressing technique, Tablet, extended release, Tablet, extended release - Oral, Powder, Powder - Respiratory (inhalation), Liquid, Intramuscular, Liquid - Intramuscular, Capsule - Respiratory (inhalation), Capsule, Solution - Intramuscular, Liquid - Respiratory (inhalation), Spray, metered, Powder, metered, Powder, metered - Respiratory (inhalation), Intravenous, Spray, metered - Respiratory (inhalation), Aerosol, spray - Oral, Aerosol, spray, Spray, Spray - Oral, Aerosol, metered - Intrabronchial, Nasal, Inhalant - Oral, Inhalant, Solution - Nasal, Inhalant - Respiratory (inhalation), Solution - Oral, Solution - Intravenous, Liquid - Intravenous, Liquid - Oral, Inhalant - Nasal
Bronchospasm, Exercise-Induced
2.0 mg/mL, , 2.5 mg/mL, 0.09 mg, 3.0 mg/mL, 2.0 mg, 4.0 mg, 8.0 mg, 0.75 mg/mL, 1.5 mg/mL, 25.0 mg/mL, 0.63 mg/mL, 1.25 mg/mL, 0.108 mg, 5.0 mg/mL, 2.4 mg, 0.045 mg, 3.0 mg, 0.4 mg, 0.2 mg, 0.1 mg, 0.05 %, 0.1 %, 0.2 %, 0.83 mg/mL, 0.12 mg, 4.8 mg, 0.00009 mg/mg, 1.0 mg/mL, 0.1 mg/dose, 0.5 mg/mL, 0.2 mg/pump actuation, 0.097 mg/pump actuation, 0.1 mg/pump actuation, 0.4 mg/mL, 0.25 mg/mL, 0.12 mg/pump actuation
, Oral, Syrup, Syrup - Oral, Respiratory (inhalation), Solution, Aerosol, metered, Aerosol, metered - Respiratory (inhalation), Tablet, Tablet - Oral, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Solution - Respiratory (inhalation), Intrabronchial, Solution - Intrabronchial, Aerosol, metered - Oral, Occlusive dressing technique, Syrup - Occlusive dressing technique, Tablet, extended release, Tablet, extended release - Oral, Powder, Powder - Respiratory (inhalation), Liquid, Intramuscular, Liquid - Intramuscular, Capsule - Respiratory (inhalation), Capsule, Solution - Intramuscular, Liquid - Respiratory (inhalation), Spray, metered, Powder, metered, Powder, metered - Respiratory (inhalation), Intravenous, Spray, metered - Respiratory (inhalation), Aerosol, spray - Oral, Aerosol, spray, Spray, Spray - Oral, Aerosol, metered - Intrabronchial, Nasal, Inhalant - Oral, Inhalant, Solution - Nasal, Inhalant - Respiratory (inhalation), Solution - Oral, Solution - Intravenous, Liquid - Intravenous, Liquid - Oral, Inhalant - Nasal
Chronic Obstructive Pulmonary Disease
2.0 mg/mL, , 2.5 mg/mL, 0.09 mg, 3.0 mg/mL, 2.0 mg, 4.0 mg, 8.0 mg, 0.75 mg/mL, 1.5 mg/mL, 25.0 mg/mL, 0.63 mg/mL, 1.25 mg/mL, 0.108 mg, 5.0 mg/mL, 2.4 mg, 0.045 mg, 3.0 mg, 0.4 mg, 0.2 mg, 0.1 mg, 0.05 %, 0.1 %, 0.2 %, 0.83 mg/mL, 0.12 mg, 4.8 mg, 0.00009 mg/mg, 1.0 mg/mL, 0.1 mg/dose, 0.5 mg/mL, 0.2 mg/pump actuation, 0.097 mg/pump actuation, 0.1 mg/pump actuation, 0.4 mg/mL, 0.25 mg/mL, 0.12 mg/pump actuation
, Oral, Syrup, Syrup - Oral, Respiratory (inhalation), Solution, Aerosol, metered, Aerosol, metered - Respiratory (inhalation), Tablet, Tablet - Oral, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Solution - Respiratory (inhalation), Intrabronchial, Solution - Intrabronchial, Aerosol, metered - Oral, Occlusive dressing technique, Syrup - Occlusive dressing technique, Tablet, extended release, Tablet, extended release - Oral, Powder, Powder - Respiratory (inhalation), Liquid, Intramuscular, Liquid - Intramuscular, Capsule - Respiratory (inhalation), Capsule, Solution - Intramuscular, Liquid - Respiratory (inhalation), Spray, metered, Powder, metered, Powder, metered - Respiratory (inhalation), Intravenous, Spray, metered - Respiratory (inhalation), Aerosol, spray - Oral, Aerosol, spray, Spray, Spray - Oral, Aerosol, metered - Intrabronchial, Nasal, Inhalant - Oral, Inhalant, Solution - Nasal, Inhalant - Respiratory (inhalation), Solution - Oral, Solution - Intravenous, Liquid - Intravenous, Liquid - Oral, Inhalant - Nasal

Warnings

There are 20 known major drug interactions with Ipratropium Bromide.
Common Ipratropium Bromide Drug Interactions
Drug Name
Risk Level
Description
Hydroxyzine
Major
The risk or severity of QTc prolongation can be increased when Salbutamol is combined with Hydroxyzine.
Mobocertinib
Major
The risk or severity of QTc prolongation can be increased when Salbutamol is combined with Mobocertinib.
Ziprasidone
Major
The risk or severity of QTc prolongation can be increased when Salbutamol is combined with Ziprasidone.
1-benzylimidazole
Minor
The risk or severity of hypertension can be increased when Salbutamol is combined with 1-benzylimidazole.
2,5-Dimethoxy-4-ethylamphetamine
Minor
The risk or severity of hypertension can be increased when Salbutamol is combined with 2,5-Dimethoxy-4-ethylamphetamine.
Ipratropium Bromide Toxicity & Overdose RiskThe amount of ipratropium that would be toxic to mice after being taken orally is 1500mg/kg. It is unlikely to overdose on ipratropium due to its poor absorption rate. Ipratropium does not appear to cause cancer, birth defects, or genetic mutation. High doses of ipratropium have been linked to a decrease in fertility rates.
image of a doctor in a lab doing drug, clinical research

Ipratropium Bromide Novel Uses: Which Conditions Have a Clinical Trial Featuring Ipratropium Bromide?

282 active clinical trials are presently investigating the utility of Ipratropium Bromide in alleviating Asthma, Bronchospasm and Perennial Allergic Rhinitis (PAR).
Condition
Clinical Trials
Trial Phases
Chronic Obstructive Pulmonary Disease
76 Actively Recruiting
Phase 3, Phase 1, Phase 2, Not Applicable, Early Phase 1, Phase 4
Bronchospasm, Exercise-Induced
0 Actively Recruiting
Asthma
92 Actively Recruiting
Phase 1, Phase 4, Early Phase 1, Phase 2, Not Applicable, Phase 3
prophylaxis of Bronchospasm
0 Actively Recruiting
Influenza
29 Actively Recruiting
Not Applicable, Phase 4, Phase 2, Phase 1, Phase 3
Hyperkalemia
4 Actively Recruiting
Phase 3, Not Applicable, Phase 2, Phase 1
Bronchitis, Chronic
0 Actively Recruiting
excess mucus or phlegm
0 Actively Recruiting
Bronchodilator Agents
0 Actively Recruiting
Pneumonia
16 Actively Recruiting
Not Applicable, Early Phase 1, Phase 2
Bronchial Spasm
0 Actively Recruiting
Asthma
1 Actively Recruiting
Phase 2
Airway secretion clearance therapy
0 Actively Recruiting
Respiratory Sounds
5 Actively Recruiting
Phase 2, Phase 3
Asthma
1 Actively Recruiting
Phase 4
Asthma, Exercise-Induced
0 Actively Recruiting
Emphysema
4 Actively Recruiting
Phase 2, Not Applicable
Bronchitis
0 Actively Recruiting
Acute Bronchitis
7 Actively Recruiting
Phase 4, Not Applicable, Phase 3, Early Phase 1
Bronchodilation
0 Actively Recruiting

Ipratropium Bromide Reviews: What are patients saying about Ipratropium Bromide?

5Patient Review
10/13/2014
Ipratropium Bromide for COPD with Chronic Bronchitis
This medication is a life-saver for those with emphysema and/or bronchitis. It quickly clears the lungs and stops coughing fits, allowing me to live a normal life for over eight years now.
5Patient Review
6/4/2022
Ipratropium Bromide for Prevention of Bronchospasm with Chronic Bronchitis
Ipratropium has completely changed my quality of life for the better. I had given up hope that anything could help me after 43 years and three surgeries, but this medication was a godsend.
5Patient Review
10/20/2014
Ipratropium Bromide for Chronic Obstructive Lung Disease
This medication, used in conjunction with Albuterol Sulfate, helped me very quickly. I was pleased with the results.
4.3Patient Review
9/23/2013
Ipratropium Bromide for Asthma
I get severe muscle cramps as a side effect, but the results for my asthma have been great.
4.3Patient Review
1/3/2015
Ipratropium Bromide for Chronic Obstructive Lung Disease
I use this in nebulizer form in combination with albuterol. I find that it works for a longer period of time than the rescue inhaler (albuterol only). However, I'm curious if there is a stronger combo available since the percentage of IB contained in one dose is so tiny (0.0173%).
4Patient Review
10/4/2010
Ipratropium Bromide for Chronic Obstructive Asthma
I used vials of 0.5 mg with 3 mg albuterol in a nebulizer. At first, this was really helpful for my bronchitis and asthma. However, after the third and fourth use I developed severe edema in my legs, ankles, and feet to the point where it hurt to walk. This is apparently a rare reaction, but it's serious enough that I don't want to use the rest of what I have.
4Patient Review
8/21/2013
Ipratropium Bromide for COPD with Chronic Bronchitis
I have a long-standing history of asthma, COPD and chronic bronchitis. So far, the combination of this treatment and 3.0 albuterol via nebulizer has been successful in keeping me out of urgent care centers.
4Patient Review
5/4/2012
Ipratropium Bromide for Chronic Obstructive Lung Disease
While this treatment has helped my breathing, it unfortunately also causes my nerves to feel frayed.
4Patient Review
8/22/2009
Ipratropium Bromide for Asthma
I use this inhaler medication in conjunction with Albuterol and it's been working great!
4Patient Review
1/12/2009
Ipratropium Bromide for Chronic Obstructive Asthma
I've just started this treatment, and I'm curious about what ingredients are in it (e.g., steroids).
3.7Patient Review
8/29/2015
Ipratropium Bromide for Asthma
The nebulizer with the Salbutamol Sulphate and ipratropium bromide inhalation solution has been helpful, but I have noticed some concerning side effects. For instance, it makes me dizzy and it's hard to concentrate.
3Patient Review
3/16/2013
Ipratropium Bromide for Asthma
This medicine caused me to cough when I inhaled it, making it difficult to fully take a breath. My mouth also felt really dry afterwards.
3Patient Review
1/21/2019
Ipratropium Bromide for Bronchospasm Prevention with COPD
I'm still getting used to this medication, but I am already seeing some improvement in my shortness of breath.
3Patient Review
7/27/2009
Ipratropium Bromide for Chronic Obstructive Lung Disease
Though this medication did not relieve my shortness of breath, it unfortunately seems to have made it worse. Is there sulfur in this medicine?
2.7Patient Review
5/9/2010
Ipratropium Bromide for Asthma
This medication does a fair job at relieving my asthma symptoms; however, it comes with the very unpleasant side-effect of causing painful leg cramps that last for days. I've tried drinking tonic water as my doctor recommended, but it doesn't help.
2.7Patient Review
9/15/2015
Ipratropium Bromide for Emphysema
My first time trying this, my breathing got worse. I tried blowing into ????? but saw only a slight improvement. Will try again later and see what happens.
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about ipratropium bromide

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What are the side effects of ipratropium bromide?

"The following are common symptoms of an ulcer: dizziness, nausea, heartburn, constipation, dry mouth, difficulty urinating, pain when urinating, and frequent need to urinate."

Answered by AI

Is Albuterol the same as ipratropium bromide?

"Both Albuterol and Ipratropium bromide work quickly to provide relief from severe symptoms and breathing difficulties. Ipratropium bromide is an anticholinergic medication, while albuterol is a short-acting beta2- adrenergic agonist."

Answered by AI

Is ipratropium bromide considered a steroid?

"Atrovent (ipratropium) is not a steroid. It is an anticholinergic, which is a type of medication that works differently than steroids to treat runny nose and allergies."

Answered by AI

What is a ipratropium bromide used for?

"Ipratropium is a medication that is used to help manage the symptoms of various lung diseases, such as asthma, bronchitis, and emphysema. It can also be used to help treat blockages in air flow and to prevent the worsening of chronic obstructive pulmonary disease (COPD)."

Answered by AI

Clinical Trials for Ipratropium Bromide

Image of Stanford University in Stanford, United States.

MoblO2 for Chronic Lung Diseases

18+
All Sexes
Stanford, CA
Many patients with chronic lung disease (e.g., chronic obstructive pulmonary disease (COPD) or interstitial lung disease (ILD)) require supplemental oxygen (O2) at some point during their disease course. Practitioners prescribe O2 to patients with chronic lung disease in hopes of the following: 1) that it will limit desaturation events and combat breathlessness, thus preventing the frustratingly slow pace and numerous rest breaks patients are forced to adopt while doing even simple tasks; 2) that it will allow patients to be more active physically (perhaps increase their ability to exercise) and socially (perhaps leave the home more often); 3) that it will stave off putative complications of hypoxemia (e.g., cognitive dysfunction, pulmonary hypertension) and 4) that it will improve health-related quality of life (HRQL). However, despite the rationale for O2, and prescribers' good intentions, patients generally view O2 with frustration and fear - it threatens their HRQL, which is already impaired by having a condition that imposes itself on every aspect of their lives. Nasal cannulas and delivery devices call unwanted attention to patients when they are out in public. O2 users feel stigmatized and are often viewed as "smokers who get what they deserve, even if they never smoked a day in their lives" - or as disabled, sick or even infectious. O2 steals patients' independence, forcing them to plan their lives around it. The anxiety that patients and their caregivers experience around running out of oxygen, or not getting enough, immobilizes them and restricts participation in activities outside of the home. O2 disrupts the home environment, adding stress, and creating a burden for patients' caregiver-loved-ones who are often saddled with the responsibility of ensuring adequate equipment and supply of O2, and O2 is a constant reminder to patients they are living with a condition that could shorten their lives. O2 delivery equipment is typically heavy, unwieldy and intimidating. Different recommendations (e.g., insurance companies use 88% as a cut-off for SpO2, while many practitioners focus on 90%) make it confusing for patients, which almost certainly affects adherence. O2-requiringpatients are starving for things that can make their lives easier. An auto-adjusting O2 delivery device - one that automatically delivers the correct amount of O2 to maintain blood oxygen at desired, pre-set levels - would alleviate the need for patients to constantly (incessantly for many) monitor their peripheral oxygen saturation (SpO2) and adjust O2flow to meet the demands as exertion levels vary . The MoblO2 device is a battery-operated, light-weight, closed-loop O2 delivery device that houses a regulator (which attaches to compressed gas O2 tanks) and adjusts O2 flow to meet a pre-set blood oxygen level. A pulse oximeter is worn on the ear and transmits via Bluetooth to the device, which adjusts an internal valve to control flow on a second-to-second basis. The user sets the dial to the highest flow of O2 needed to meet the demands of activities they might perform (up to 15 liters per minute), and the device adjusts flow, up to the pre-set level to maintain SpO2 at a preset level (e.g., \> 90%). To conserve O2 supply in the tank - and to avoid over-oxygenation (which could be problematic for a small percentage of patients with the most severe COPD) - the MoblO2 begins to limit O2 flow at a SpO2 of 93%. The device can be manually over-ridden by the user, and should the battery run out - or the device fail for some unforeseen reason - the default position is valve open, so the users receive whatever flow of oxygen has been set on the dial. Given the substantial burdens of O2 on patients and their families, the hassles patients describe with having to monitor their SpO2 and repeatedly adjust the flow of O2 to meet their needs, patients and experts around the world have called for improvements in O2 delivery equipment. The MoblO2 is just such a remarkable improvement and a giant step forward in helping to ease the burdens of O2 on patients who require it. The purpose of this study is to investigate the effects of the MoblO2 O2 delivery device on a range of outcomes, including physical activity, amount (liters) O2 use; maintenance of adequate SpO2 levels; patient reported outcomes including symptoms, HRQL and satisfaction with the MoblO2 O2 device.
Waitlist Available
Has No Placebo
Stanford UniversityJeff Swigris, DO, MSMinnesota Health Solutions
Image of National Institutes of Health Clinical Center in Bethesda, United States.

BPL-1357 for Flu

18 - 55
All Sexes
Bethesda, MD
Background: Influenza (flu) infections are a serious global health threat. Each year, between 3 and 5 million people get the flu, and up to 500,000 die from it. Current vaccines protect against seasonal flus, but broader vaccines are needed to protect against potential flu pandemics. Objective: To test an experimental flu vaccine. Eligibility: Healthy people aged 18 to 55 years. Design: The study will last 5 to 8 months and has 2 phases, A and B. The study vaccine will be given either as a shot in the arm or as a nasal spray. Participants will receive 1 of 3 combinations: (1) study vaccine in the nose and placebo in the arm; (2) placebo in the nose and study vaccine in the arm; or (3) placebo in the nose and placebo in the arm. A placebo is just like the real vaccine but contains no active ingredients. Phase A: Participants will have 5 clinic visits over 56 days. They will receive a shot and a nasal spray at 2 of the visits, 28 days apart. At each visit, they will have a physical exam, with tests of their blood, urine, and nasal secretions. They will check their temperature at home and record any symptoms for 7 days after each vaccine. Phase B: Participants will stay in the hospital for at least 9 days. They will be infected with a flu virus. They will provide blood, urine, and nasal fluid samples. They will have tests of their heart function. They will remain in the hospital until they test negative for the flu 2 days in a row. They will have 2 follow-up visits, 4 and 8 weeks after leaving the hospital.
Phase 2
Waitlist Available
National Institutes of Health Clinical Center (+1 Sites)Luca T Giurgea, M.D.
Have you considered Ipratropium Bromide clinical trials? We made a collection of clinical trials featuring Ipratropium Bromide, we think they might fit your search criteria.Go to Trials
Image of Vanderbilt University Medical Center in Nashville, United States.

High vs. Standard Dose Influenza Vaccines for Flu

18+
All Sexes
Nashville, TN
This will be a follow-up study to the "Comparison of High Dose vs. Standard Dose Influenza Vaccine in Lung Allograft Recipient" study (DMID Protocol Number 22-0014) at Vanderbilt University Medical Center. Lung transplantation is a life-saving therapy for patients with advanced lung disease, and is also associated with an improvement in quality of life. However, due to the need for life-long immunosuppression to prevent acute cellular rejection and chronic lung allograft dysfunction ("chronic rejection"), lung transplant recipients are at risk for developing major infections. In fact, one-year survival is 85%, with infection being the leading cause of death within the first year post-transplant. We will conduct a follow-up phase II, randomized, double-blind trial to assess the impact of subsequent administration of two doses of HD-IIV compared to two doses of SD-IIV among lung recipients during the early post-transplant period. Demonstration of improved immunogenicity from two doses of HD-IIV over consecutive influenza seasons would provide potential broad benefit in reducing influenza disease and its associated complications in lung transplant recipients. Moreover, studying vaccine immunogenicity and safety in the same participants over consecutive years can provide insight into the influence of immunosuppression levels and allograft aging on vaccine-mediated immune modulation. This proposed study design will contribute significantly to influenza vaccination guidance and policy for the highly vulnerable lung transplant population. This proposed study is designed to address several key knowledge gaps in vaccine-mediated protection of lung transplant recipients against influenza: * Is there increased immunogenicity with administration of one or two doses of HD-IIV or SD-IIV in the subsequent season compared to two doses of HD-IIV or SD-IIV in the first season? * What is the durability of the humoral and cellular immune response between influenza seasons and does two doses of HD-IIV or SD-IIV sustain higher HAI titers compared to two doses of HD-IIV or SD-IIV in the first season? * What is the impact of maintenance immunosuppression levels on influenza vaccine immunogenicity within the same participant? * Will the optimal immunogenic vaccination strategy be associated with an acceptable long-term safety profile over successive influenza seasons, including injection-site and systemic reactions, allosensitization, and organ rejection?
Phase 2
Recruiting
Vanderbilt University Medical CenterNatahsa Halasa, MD, MPH
Image of Altasciences Inc - Kansas City in Overland Park, United States.

VNT-101 for Safety and Tolerability Study

18 - 59
All Sexes
Overland Park, KS
A randomized, double-blind, placebo-controlled Phase 1 study conducted at a single center with approximately 78 healthy adults aged 18-59 years. Part 1 Single Ascending Dose (SAD) will enroll 48 participants into six cohorts (S1-S6) to receive single oral doses of VNT-101 (100-1500 mg) or placebo under fasting or fed (S5 only) conditions. Part 2 Multiple Ascending Dose (MAD) will enroll 30 participants into three cohorts (M1-M3) to receive multiple oral doses of VNT-101 (250-750 mg BID Days 1-5, QD Day 6) or placebo under fasting conditions. Dose escalation in both parts will proceed after Protocol Safety Review Team (PSRT) review. The primary objective for Part 1 is to evaluate the safety and tolerability of single ascending oral (SAD) doses of VNT-101 in healthy adult participants under either fasting or fed conditions. The primary objective for part 2 is to evaluate the safety and tolerability of multiple ascending oral (MAD) doses of VNT-101 in healthy adult participants.
Phase 1
Recruiting
Altasciences Inc - Kansas City
Have you considered Ipratropium Bromide clinical trials? We made a collection of clinical trials featuring Ipratropium Bromide, we think they might fit your search criteria.Go to Trials
Have you considered Ipratropium Bromide clinical trials? We made a collection of clinical trials featuring Ipratropium Bromide, we think they might fit your search criteria.Go to Trials
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security